Because the reduction of serum adiponectin level correlates with clinical signs and biochemical components of the MetS, measurement of serum adiponectin could become a noninvasive and accessible method of risk assessment for MetS early-onset in healthy obese patients. This evidence concerns the gene ADIPOQ and metabolic syndrome.